Skip to main content

Table 5 The association of statins with VAF

From: Pharmaceutical prevention strategy for arteriovenous fistula and arteriovenous graft failure

Author Design N (Control) Exposure Timing Outcome (duration) VAF development
Wanner et al [79]
(4D study)
Placebo-controlled 1255 (636) Atorvastatin
20 mg/day
Incidence of cardiovascular events (4 years) NA
Fellstrom et al [78]
(AURORA trial)
Placebo-controlled 2776 (1385) Rosuvastatin
10 mg/day
Pre
Incidence of VA procedure (3.8 years) Equivalent risk
(RR 1.10, 95% CI 0.95–1.27, P = 0.19)
Baigent et al [76]
(SHARP trial)
Placebo-controlled 9270 (4620) Simvastatin
20 mg/day
+ Ezetimibe
10 mg/day
Pre
Incidence of VA occulusive events (5 years) Unclear
(29.7% vs. 33.5%, RR 0.87, 95% CI 0.75–1.00, P = 0.05)
Herrington et al [75]
(Combined analysis of AURORA & SHARP trial)
Placebo-controlled 1432 (725) Rosuvastatin 10 mg/day
or
Simvastatin
20 mg/day
+ Ezetimibe
10 mg/day
Pre
Incidence of VA occulusive events (4.5 years) Equivalent risk
(29.3% vs. 30.5%, RR 0.95, 95% CI 0.85–1.05, P = 0.29)
  1. VAF vascular access failure, VA vascular access, RR relative risk, HR hazard ratio, CI confidential interval, Pre pre-operative period, NA not available, 4D Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis, AURORA A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events, SHARP The Study of Heart and Renal Protection